LGD-3303
Muscle & Strength · SARM
Tier D
Bottom line
Read Off Label grades LGD-3303 as D (3.3/10) based on very weak evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Preclinical osteoporosis candidate from Ligand.
Studied, labeled, or reported-use context: No established human dosing — NOT FDA-approved; gray market; banned sport; not individualized guidance.
Citation correction in progress
1 PubMed link was found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Preclinical osteoporosis candidate from Ligand. Never advanced to clinical development. Exists in the research-chemical market primarily as a novelty; essentially no safety or efficacy information in humans.
Mechanism
Strong non-steroidal SARM from Ligand Pharmaceuticals — more androgenic than LGD-4033; bone and muscle anabolic in preclinical; no meaningful human trial program
Studied, labeled, or reported dose & route
No established human dosing
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about LGD-3303's effects?
- Read Off Label rates the evidence for LGD-3303 as Very Weak and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Preclinical osteoporosis candidate from Ligand.
- What safety findings are reported for LGD-3303?
- LGD-3303 has a unclear risk profile in the database. Unknown (preclinical suggests significant AR activity; no human safety data) Legal status: NOT FDA-approved; gray market; banned sport.
- What doses or routes are reported for LGD-3303?
- No established human dosing This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does LGD-3303 work?
- Strong non-steroidal SARM from Ligand Pharmaceuticals — more androgenic than LGD-4033; bone and muscle anabolic in preclinical; no meaningful human trial program
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.